Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma
Purpose This study was performed in order to evaluate the incidence of radiation retinopathy and optic neuropathy occurring after proton beam therapy for uveal melanoma. Methods Included in this study were all patients who had been treated with primary proton beam therapy for uveal melanoma at the o...
Gespeichert in:
| Veröffentlicht in: | Graefe's archive for clinical and experimental ophthalmology 2016-09, Vol.254 (9), p.1787-1792 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1792 |
|---|---|
| container_issue | 9 |
| container_start_page | 1787 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 254 |
| creator | Seibel, Ira Cordini, Dino Hager, Annette Tillner, Johanna Riechardt, Aline I. Heufelder, Jens Davids, Anja M. Rehak, Matus Joussen, Antonia M. |
| description | Purpose
This study was performed in order to evaluate the incidence of radiation retinopathy and optic neuropathy occurring after proton beam therapy for uveal melanoma.
Methods
Included in this study were all patients who had been treated with primary proton beam therapy for uveal melanoma at the oncology service between May 1998 and June 2014 with a minimum follow-up of 12 months. Excluded were all patients who underwent re-irradiation, or vitrectomy due to exudative retinal detachment or for tumor-resection.
Results
During this period, 1127 patients matched the inclusion criteria, of whom 768 (68.1 %) and 463 (41.0 %) developed radiation retinopathy and optic neuropathy after a median time of 18.9 months (2.0–99.84 months) and 19.8 months (0.2–170.4 months), respectively. Mean follow-up was 53.4 months (12–170.4 months). Included were 558 men (49.5 %) and 569 women (50.5 %). Mean age was 61 years (16–89 years). Visual acuity slightly decreased from initial levels of 0.3 logMAR–0.4 logMAR in patients without developing any radiation-induced complication but severely decreased to 1.0 logMAR or 1.5 logMAR in the case of developing radiation retinopathy only or optic neuropathy, respectively. Independent risk factors for radiation retinopathy were a centrally ( |
| doi_str_mv | 10.1007/s00417-016-3429-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827928670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1827928670</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-28e81a14b5501cb59a59aead8f60ff9238e1eecc6444d2d82fb958c8d6bb73e23</originalsourceid><addsrcrecordid>eNqNkU1LHTEUhkNR6lX7A9yUgJtups3nJLMsorUgtAsFdyGTOamxdybTJHPh_vvmelVKoVAIBHKe854THoTOKPlICVGfMiGCqobQtuGCdY14g1ZUcNkowu4P0IooRhvN2f0ROs75kVScS_oWHTHFVauZWKH8PcEQXAkbwCnkn9hbV2LK2MeEkx2CLSFOOEEJU5xtedhiOw04ziU4PMGSXh59gYTnFEule7AjLg-Q7Lx9Clo2YNd4hLWd4mhP0aG36wzvnu8TdHd1eXtx3dx8-_L14vNN4wSRpWEaNLVU9FIS6nrZ2XrADtq3xPuOcQ0UwLlWCDGwQTPfd1I7PbR9rzgwfoI-7HPrWr8WyMWMITtY1y0gLtlQzVTHdKvIf6CUaS15Jyt6_hf6GJc01Y88US3hhOxm0z3lUsw5gTdzCqNNW0OJ2ckze3mmyjM7eUbUnvfPyUs_wvDa8WKrAmwP5FqafkD6Y_Q_U38D7c6mMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1812603002</pqid></control><display><type>article</type><title>Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Seibel, Ira ; Cordini, Dino ; Hager, Annette ; Tillner, Johanna ; Riechardt, Aline I. ; Heufelder, Jens ; Davids, Anja M. ; Rehak, Matus ; Joussen, Antonia M.</creator><creatorcontrib>Seibel, Ira ; Cordini, Dino ; Hager, Annette ; Tillner, Johanna ; Riechardt, Aline I. ; Heufelder, Jens ; Davids, Anja M. ; Rehak, Matus ; Joussen, Antonia M.</creatorcontrib><description>Purpose
This study was performed in order to evaluate the incidence of radiation retinopathy and optic neuropathy occurring after proton beam therapy for uveal melanoma.
Methods
Included in this study were all patients who had been treated with primary proton beam therapy for uveal melanoma at the oncology service between May 1998 and June 2014 with a minimum follow-up of 12 months. Excluded were all patients who underwent re-irradiation, or vitrectomy due to exudative retinal detachment or for tumor-resection.
Results
During this period, 1127 patients matched the inclusion criteria, of whom 768 (68.1 %) and 463 (41.0 %) developed radiation retinopathy and optic neuropathy after a median time of 18.9 months (2.0–99.84 months) and 19.8 months (0.2–170.4 months), respectively. Mean follow-up was 53.4 months (12–170.4 months). Included were 558 men (49.5 %) and 569 women (50.5 %). Mean age was 61 years (16–89 years). Visual acuity slightly decreased from initial levels of 0.3 logMAR–0.4 logMAR in patients without developing any radiation-induced complication but severely decreased to 1.0 logMAR or 1.5 logMAR in the case of developing radiation retinopathy only or optic neuropathy, respectively. Independent risk factors for radiation retinopathy were a centrally (<2.5 mm from sensitive structures) located tumor or a thick tumor located more than 2.5 mm from sensitive structures, while those for radiation optic neuropathy comprised a short distance and applied dose to the optic disk.
Conclusion
The risk for radiation retinopathy is higher in central uveal melanoma.
Mid-/peripheral tumors are at high risk for radiation retinopathy and maculopathy if presenting with increased thickness.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-016-3429-4</identifier><identifier>PMID: 27376824</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Germany - epidemiology ; Humans ; Incidence ; Magnetic Resonance Imaging ; Male ; Medicine ; Medicine & Public Health ; Melanoma - diagnosis ; Melanoma - mortality ; Melanoma - radiotherapy ; Middle Aged ; Oncology ; Ophthalmology ; Optic Nerve Diseases - diagnosis ; Optic Nerve Diseases - epidemiology ; Optic Nerve Diseases - etiology ; Proton Therapy - adverse effects ; Radiation Injuries - diagnosis ; Radiation Injuries - epidemiology ; Radiation Injuries - etiology ; Retinal Diseases - diagnosis ; Retinal Diseases - epidemiology ; Retinal Diseases - etiology ; Retrospective Studies ; Survival Rate - trends ; Time Factors ; Tomography, Optical Coherence ; Uveal Neoplasms - diagnosis ; Uveal Neoplasms - mortality ; Uveal Neoplasms - radiotherapy ; Visual Acuity ; Young Adult</subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2016-09, Vol.254 (9), p.1787-1792</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-28e81a14b5501cb59a59aead8f60ff9238e1eecc6444d2d82fb958c8d6bb73e23</citedby><cites>FETCH-LOGICAL-c405t-28e81a14b5501cb59a59aead8f60ff9238e1eecc6444d2d82fb958c8d6bb73e23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00417-016-3429-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00417-016-3429-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27376824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seibel, Ira</creatorcontrib><creatorcontrib>Cordini, Dino</creatorcontrib><creatorcontrib>Hager, Annette</creatorcontrib><creatorcontrib>Tillner, Johanna</creatorcontrib><creatorcontrib>Riechardt, Aline I.</creatorcontrib><creatorcontrib>Heufelder, Jens</creatorcontrib><creatorcontrib>Davids, Anja M.</creatorcontrib><creatorcontrib>Rehak, Matus</creatorcontrib><creatorcontrib>Joussen, Antonia M.</creatorcontrib><title>Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>Purpose
This study was performed in order to evaluate the incidence of radiation retinopathy and optic neuropathy occurring after proton beam therapy for uveal melanoma.
Methods
Included in this study were all patients who had been treated with primary proton beam therapy for uveal melanoma at the oncology service between May 1998 and June 2014 with a minimum follow-up of 12 months. Excluded were all patients who underwent re-irradiation, or vitrectomy due to exudative retinal detachment or for tumor-resection.
Results
During this period, 1127 patients matched the inclusion criteria, of whom 768 (68.1 %) and 463 (41.0 %) developed radiation retinopathy and optic neuropathy after a median time of 18.9 months (2.0–99.84 months) and 19.8 months (0.2–170.4 months), respectively. Mean follow-up was 53.4 months (12–170.4 months). Included were 558 men (49.5 %) and 569 women (50.5 %). Mean age was 61 years (16–89 years). Visual acuity slightly decreased from initial levels of 0.3 logMAR–0.4 logMAR in patients without developing any radiation-induced complication but severely decreased to 1.0 logMAR or 1.5 logMAR in the case of developing radiation retinopathy only or optic neuropathy, respectively. Independent risk factors for radiation retinopathy were a centrally (<2.5 mm from sensitive structures) located tumor or a thick tumor located more than 2.5 mm from sensitive structures, while those for radiation optic neuropathy comprised a short distance and applied dose to the optic disk.
Conclusion
The risk for radiation retinopathy is higher in central uveal melanoma.
Mid-/peripheral tumors are at high risk for radiation retinopathy and maculopathy if presenting with increased thickness.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Germany - epidemiology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma - diagnosis</subject><subject>Melanoma - mortality</subject><subject>Melanoma - radiotherapy</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Ophthalmology</subject><subject>Optic Nerve Diseases - diagnosis</subject><subject>Optic Nerve Diseases - epidemiology</subject><subject>Optic Nerve Diseases - etiology</subject><subject>Proton Therapy - adverse effects</subject><subject>Radiation Injuries - diagnosis</subject><subject>Radiation Injuries - epidemiology</subject><subject>Radiation Injuries - etiology</subject><subject>Retinal Diseases - diagnosis</subject><subject>Retinal Diseases - epidemiology</subject><subject>Retinal Diseases - etiology</subject><subject>Retrospective Studies</subject><subject>Survival Rate - trends</subject><subject>Time Factors</subject><subject>Tomography, Optical Coherence</subject><subject>Uveal Neoplasms - diagnosis</subject><subject>Uveal Neoplasms - mortality</subject><subject>Uveal Neoplasms - radiotherapy</subject><subject>Visual Acuity</subject><subject>Young Adult</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU1LHTEUhkNR6lX7A9yUgJtups3nJLMsorUgtAsFdyGTOamxdybTJHPh_vvmelVKoVAIBHKe854THoTOKPlICVGfMiGCqobQtuGCdY14g1ZUcNkowu4P0IooRhvN2f0ROs75kVScS_oWHTHFVauZWKH8PcEQXAkbwCnkn9hbV2LK2MeEkx2CLSFOOEEJU5xtedhiOw04ziU4PMGSXh59gYTnFEule7AjLg-Q7Lx9Clo2YNd4hLWd4mhP0aG36wzvnu8TdHd1eXtx3dx8-_L14vNN4wSRpWEaNLVU9FIS6nrZ2XrADtq3xPuOcQ0UwLlWCDGwQTPfd1I7PbR9rzgwfoI-7HPrWr8WyMWMITtY1y0gLtlQzVTHdKvIf6CUaS15Jyt6_hf6GJc01Y88US3hhOxm0z3lUsw5gTdzCqNNW0OJ2ckze3mmyjM7eUbUnvfPyUs_wvDa8WKrAmwP5FqafkD6Y_Q_U38D7c6mMA</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Seibel, Ira</creator><creator>Cordini, Dino</creator><creator>Hager, Annette</creator><creator>Tillner, Johanna</creator><creator>Riechardt, Aline I.</creator><creator>Heufelder, Jens</creator><creator>Davids, Anja M.</creator><creator>Rehak, Matus</creator><creator>Joussen, Antonia M.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160901</creationdate><title>Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma</title><author>Seibel, Ira ; Cordini, Dino ; Hager, Annette ; Tillner, Johanna ; Riechardt, Aline I. ; Heufelder, Jens ; Davids, Anja M. ; Rehak, Matus ; Joussen, Antonia M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-28e81a14b5501cb59a59aead8f60ff9238e1eecc6444d2d82fb958c8d6bb73e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Germany - epidemiology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma - diagnosis</topic><topic>Melanoma - mortality</topic><topic>Melanoma - radiotherapy</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Ophthalmology</topic><topic>Optic Nerve Diseases - diagnosis</topic><topic>Optic Nerve Diseases - epidemiology</topic><topic>Optic Nerve Diseases - etiology</topic><topic>Proton Therapy - adverse effects</topic><topic>Radiation Injuries - diagnosis</topic><topic>Radiation Injuries - epidemiology</topic><topic>Radiation Injuries - etiology</topic><topic>Retinal Diseases - diagnosis</topic><topic>Retinal Diseases - epidemiology</topic><topic>Retinal Diseases - etiology</topic><topic>Retrospective Studies</topic><topic>Survival Rate - trends</topic><topic>Time Factors</topic><topic>Tomography, Optical Coherence</topic><topic>Uveal Neoplasms - diagnosis</topic><topic>Uveal Neoplasms - mortality</topic><topic>Uveal Neoplasms - radiotherapy</topic><topic>Visual Acuity</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seibel, Ira</creatorcontrib><creatorcontrib>Cordini, Dino</creatorcontrib><creatorcontrib>Hager, Annette</creatorcontrib><creatorcontrib>Tillner, Johanna</creatorcontrib><creatorcontrib>Riechardt, Aline I.</creatorcontrib><creatorcontrib>Heufelder, Jens</creatorcontrib><creatorcontrib>Davids, Anja M.</creatorcontrib><creatorcontrib>Rehak, Matus</creatorcontrib><creatorcontrib>Joussen, Antonia M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seibel, Ira</au><au>Cordini, Dino</au><au>Hager, Annette</au><au>Tillner, Johanna</au><au>Riechardt, Aline I.</au><au>Heufelder, Jens</au><au>Davids, Anja M.</au><au>Rehak, Matus</au><au>Joussen, Antonia M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><stitle>Graefes Arch Clin Exp Ophthalmol</stitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>254</volume><issue>9</issue><spage>1787</spage><epage>1792</epage><pages>1787-1792</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>Purpose
This study was performed in order to evaluate the incidence of radiation retinopathy and optic neuropathy occurring after proton beam therapy for uveal melanoma.
Methods
Included in this study were all patients who had been treated with primary proton beam therapy for uveal melanoma at the oncology service between May 1998 and June 2014 with a minimum follow-up of 12 months. Excluded were all patients who underwent re-irradiation, or vitrectomy due to exudative retinal detachment or for tumor-resection.
Results
During this period, 1127 patients matched the inclusion criteria, of whom 768 (68.1 %) and 463 (41.0 %) developed radiation retinopathy and optic neuropathy after a median time of 18.9 months (2.0–99.84 months) and 19.8 months (0.2–170.4 months), respectively. Mean follow-up was 53.4 months (12–170.4 months). Included were 558 men (49.5 %) and 569 women (50.5 %). Mean age was 61 years (16–89 years). Visual acuity slightly decreased from initial levels of 0.3 logMAR–0.4 logMAR in patients without developing any radiation-induced complication but severely decreased to 1.0 logMAR or 1.5 logMAR in the case of developing radiation retinopathy only or optic neuropathy, respectively. Independent risk factors for radiation retinopathy were a centrally (<2.5 mm from sensitive structures) located tumor or a thick tumor located more than 2.5 mm from sensitive structures, while those for radiation optic neuropathy comprised a short distance and applied dose to the optic disk.
Conclusion
The risk for radiation retinopathy is higher in central uveal melanoma.
Mid-/peripheral tumors are at high risk for radiation retinopathy and maculopathy if presenting with increased thickness.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27376824</pmid><doi>10.1007/s00417-016-3429-4</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2016-09, Vol.254 (9), p.1787-1792 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1827928670 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Aged Aged, 80 and over Female Follow-Up Studies Germany - epidemiology Humans Incidence Magnetic Resonance Imaging Male Medicine Medicine & Public Health Melanoma - diagnosis Melanoma - mortality Melanoma - radiotherapy Middle Aged Oncology Ophthalmology Optic Nerve Diseases - diagnosis Optic Nerve Diseases - epidemiology Optic Nerve Diseases - etiology Proton Therapy - adverse effects Radiation Injuries - diagnosis Radiation Injuries - epidemiology Radiation Injuries - etiology Retinal Diseases - diagnosis Retinal Diseases - epidemiology Retinal Diseases - etiology Retrospective Studies Survival Rate - trends Time Factors Tomography, Optical Coherence Uveal Neoplasms - diagnosis Uveal Neoplasms - mortality Uveal Neoplasms - radiotherapy Visual Acuity Young Adult |
| title | Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T21%3A29%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20risk%20factors%20for%20radiation%20retinopathy%20and%20optic%20neuropathy%20after%20proton%20beam%20therapy%20for%20uveal%20melanoma&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Seibel,%20Ira&rft.date=2016-09-01&rft.volume=254&rft.issue=9&rft.spage=1787&rft.epage=1792&rft.pages=1787-1792&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-016-3429-4&rft_dat=%3Cproquest_cross%3E1827928670%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1812603002&rft_id=info:pmid/27376824&rfr_iscdi=true |